BRPI0407234A - Heterociclos substituìdos - Google Patents

Heterociclos substituìdos

Info

Publication number
BRPI0407234A
BRPI0407234A BR0407234-0A BRPI0407234A BRPI0407234A BR PI0407234 A BRPI0407234 A BR PI0407234A BR PI0407234 A BRPI0407234 A BR PI0407234A BR PI0407234 A BRPI0407234 A BR PI0407234A
Authority
BR
Brazil
Prior art keywords
substituted heterocycles
heterocycles
substituted
medicaments
asthma
Prior art date
Application number
BR0407234-0A
Other languages
English (en)
Inventor
Marc Stadler
Stephan Seip
Hartwig Mueller
Anke Mayer-Bartschmid
Michael-Alexander Bruening
Jordi Benet-Buchholz
Hiroko Togame
Reiko Dodo
Peter Reinemer
Kevin Bacon
Kinji Fuchikami
Satoko Matsukawa
Klaus Urbahns
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of BRPI0407234A publication Critical patent/BRPI0407234A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces

Abstract

"HETEROCICLOS SUBSTITUìDOS". A presente invenção refere-se a heterociclos substituídos, processos para sua preparação, e seu uso em medicamentos, especialmente para o tratamento de doença inflamatória, isto é asma, ou câncer.
BR0407234-0A 2003-02-14 2004-02-06 Heterociclos substituìdos BRPI0407234A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03003495 2003-02-14
EP03007594 2003-04-02
PCT/EP2004/001097 WO2004071382A2 (en) 2003-02-14 2004-02-06 Substituted heterocycles

Publications (1)

Publication Number Publication Date
BRPI0407234A true BRPI0407234A (pt) 2006-01-31

Family

ID=32870763

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0407234-0A BRPI0407234A (pt) 2003-02-14 2004-02-06 Heterociclos substituìdos

Country Status (16)

Country Link
US (2) US20060229353A1 (pt)
EP (1) EP1597262B1 (pt)
JP (1) JP4795931B2 (pt)
KR (1) KR20050098928A (pt)
CN (1) CN1845925B (pt)
AT (1) ATE448232T1 (pt)
AU (1) AU2004212296B2 (pt)
BR (1) BRPI0407234A (pt)
CA (1) CA2515940C (pt)
DE (1) DE602004024037D1 (pt)
ES (1) ES2336562T3 (pt)
HK (1) HK1096392A1 (pt)
IL (1) IL169897A0 (pt)
IN (1) IN228043B (pt)
MX (1) MX272108B (pt)
WO (1) WO2004071382A2 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1341414T3 (da) 2000-11-16 2013-03-25 Univ California Marint actinomycet-taxon til opdagelse af medikamenter og fermenteringsprodukter
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
ZA200600473B (en) * 2003-06-20 2007-04-25 Univ California Salinosporamides and methods for use thereof
BRPI0411677A (pt) * 2003-06-20 2006-08-29 Nereus Pharmaceuticals Inc métodos de uso de compostos heterocìclicos [3.2.0] e seus análogos
WO2005099687A2 (en) 2004-04-09 2005-10-27 President And Fellows Of Harvard College Analogs of salinosporamide a
WO2006028525A2 (en) * 2004-04-30 2006-03-16 Nereus Pharmaceuticals, Inc. [3.2.0] heterocyclic compounds and methods of using the same
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
KR20070041742A (ko) * 2004-07-12 2007-04-19 바이엘 크롭사이언스 아게 살진균제 및 살충제로서의 치환된 2-피롤리돈 유도체
BRPI0517134A2 (pt) * 2004-12-03 2011-10-11 Nereus Pharmaceuticals Inc métodos de uso de compostos heterocìclicos [ 3.2.0 ] e seus análogos
BRPI0517135B1 (pt) 2004-12-03 2022-04-19 Triphase Research And Development I Corp Composições e métodos para tratar doenças neoplásticas
WO2006118973A2 (en) * 2005-04-29 2006-11-09 Nereus Pharmaceuticals, Inc. Methods of using heterobyclic compounds for treatment of rectal cancer
US7465720B2 (en) 2005-09-12 2008-12-16 President And Fellows Of Harvard College Proteasome inhibiting β-lactam compounds
JP2009532484A (ja) 2006-04-06 2009-09-10 ネレアス ファーマシューティカルズ インコーポレイテッド サリノスポラミドａ及びその類縁体の全合成
US7824698B2 (en) * 2007-02-02 2010-11-02 Nereus Pharmaceuticals, Inc. Lyophilized formulations of Salinosporamide A
WO2008137780A2 (en) * 2007-05-04 2008-11-13 Nereus Pharmaceuticals, Inc. Use of [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases
US8394816B2 (en) * 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
EP2088205A1 (en) 2008-02-11 2009-08-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) PSMB10: A diagnosis marker and therapeutic target of chronic rejection.
KR20100131475A (ko) 2008-03-07 2010-12-15 니리어스 파마슈티컬즈, 인코퍼레이션 살리노스포라마이드 ａ 및 그의 유사체들의 전합성
CN102089312A (zh) * 2008-05-12 2011-06-08 尼瑞斯药品公司 作为蛋白酶体抑制剂的Salinosporamide衍生物
EP3021120A1 (en) 2009-02-20 2016-05-18 Michael P. Lisanti Diagnosis, prognosis, therapeutics and methods for treating neoplastic deiseases comprising determining the level of caveolin-1 in a stromal cell sample
US9126997B1 (en) 2010-09-07 2015-09-08 Northwestern University Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
US9827246B2 (en) 2011-10-28 2017-11-28 Millennium Pharmaceuticals, Inc. Biomarkers of response to NAE inhibitors
CN104126017A (zh) 2011-11-11 2014-10-29 米伦纽姆医药公司 对蛋白酶体抑制剂的反应的生物标记
EP2810066B1 (en) 2012-01-24 2019-07-31 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
GB2523211B (en) 2012-01-27 2020-03-18 Univ Jefferson MCT protein inhibitor-related prognostic and therapeutic methods
CA2886783A1 (en) 2012-10-01 2014-04-10 Millennium Pharmaceuticals, Inc. Biomarkers and methods to predict response to inhibitors and uses thereof
US10022372B2 (en) 2013-04-19 2018-07-17 Thomas Jefferson University Caveolin-1 related methods for treating glioblastoma with temozolomide
EP3339291A1 (en) * 2016-12-22 2018-06-27 Vita Api Proteasome inhibiting ss-lactam prodrugs useful for the treatment of cancer and neurodegenerative disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335358B1 (en) * 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
DK1341414T3 (da) * 2000-11-16 2013-03-25 Univ California Marint actinomycet-taxon til opdagelse af medikamenter og fermenteringsprodukter

Also Published As

Publication number Publication date
MXPA05008478A (es) 2005-10-18
HK1096392A1 (en) 2007-06-01
CN1845925B (zh) 2010-11-03
JP2006517934A (ja) 2006-08-03
JP4795931B2 (ja) 2011-10-19
IN2005DE03350A (pt) 2007-06-01
ES2336562T3 (es) 2010-04-14
IN228043B (pt) 2009-02-13
IL169897A0 (en) 2007-07-04
EP1597262B1 (en) 2009-11-11
WO2004071382A2 (en) 2004-08-26
AU2004212296A1 (en) 2004-08-26
CA2515940A1 (en) 2004-08-26
DE602004024037D1 (de) 2009-12-24
AU2004212296B2 (en) 2010-06-17
US20110015248A1 (en) 2011-01-20
ATE448232T1 (de) 2009-11-15
KR20050098928A (ko) 2005-10-12
MX272108B (es) 2009-11-25
CN1845925A (zh) 2006-10-11
EP1597262A2 (en) 2005-11-23
WO2004071382A3 (en) 2005-01-06
CA2515940C (en) 2011-12-06
US20060229353A1 (en) 2006-10-12

Similar Documents

Publication Publication Date Title
ATE448232T1 (de) Substituierte heterozyklen
LTC1620113I2 (lt) Ivermektino topinė kompozicija, skirta dermatologinių susirgimų gydymui
UA85559C2 (en) Aminobenzophenone compounds
NO20073574L (no) Triazolsubstituerte aminobenzofenonforbindelser
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
DE50310516D1 (de) Fredericamycin-derivate
CY1106476T1 (el) Υποκατεστημενες διυδροκιναζολινες με αντι-ιικες ιδιοτητες
NO20082594L (no) Pyrimidinylbenzotiofenforbindelser
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
ATE453642T1 (de) Substituierte phenylaminopyrimidine
BRPI0407662B8 (pt) derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
IL209879A0 (en) Substituted pteridines ,pharmaceutical compositions containing them and their use in the manufacture of medicaments for treating inflammatory diseases
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
ATE380188T1 (de) Substituierte chinolone
SE0302304D0 (sv) Novel compounds
ATE475651T1 (de) Aryl-substituierte heterozyklen und ihre verwendung
DE502005007472D1 (de) Desoxo-nonadepsipeptide
ATE455789T1 (de) Substituierte nonadepsipeptide
DE502005005652D1 (de) Heterocyclyl-substituierte nonadepsipeptide
SE0300457D0 (sv) Novel compounds
TW200504051A (en) Novel acridine derivatives and their use as medicaments
ATE553088T1 (de) Substituierte chinolone ii
ATE481392T1 (de) Benzimidazolderivate zur behandlung entzündlicher erkrankungen
DK1904511T3 (da) Homogemcitabin

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 9A E 10A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2257 DE 08/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A E 16A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.